DNA
Ginkgo Bioworks
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 4
Revenue Plunges
Price Hits New Low
Price Hits 52-week low
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About DNA
Ginkgo Bioworks Holdings, Inc.
A leading platform for cell programming and biosecurity
Biological Technology
10/22/2020
09/17/2021
New York Stock Exchange
834
12-31
Common stock
27 Drydock Avenue, 8th Floor, Boston, MA 02210
--
Ginkgo Bioworks Holdings, Inc., was incorporated and registered in Delaware on October 22, 2020. Ginkgo Bioworks is a leading platform for cellular programming, providing flexible end-to-end services that solve challenges for organizations in diverse markets such as food and agriculture, pharmaceuticals, industrial and specialty chemicals. Concentric by Ginkgo, Ginkgo's biosafety and public health division, is building a global biosafety infrastructure to empower governments, communities and public health leaders to prevent, detect and respond to a wide variety of biological threats.
Company Financials
EPS
DNA has released its 2024 Q4 earnings. EPS was reported at -2.00, versus the expected -1.30, missing expectations. The chart below visualizes how DNA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DNA has released its 2024 Q4 earnings report, with revenue of 43.85M, reflecting a YoY change of 26.16%, and net profit of -107.53M, showing a YoY change of 49.20%. The Sankey diagram below clearly presents DNA’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
